Eosinophilic Esophagitis Market Insight, Epidemiology And Market Forecast -2030

August 23 11:40 2021
Eosinophilic Esophagitis Market Insight, Epidemiology And Market Forecast -2030
DelveInsight Business Research LLP
DelveInsight’s ‘Eosinophilic Esophagitis Market’ report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of EoE in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Eosinophilic Esophagitis Market Insight, Epidemiology and Market Forecast -2030

Eosinophilic Esophagitis Market

The EoE market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted EoE market Size from 2018 to 2030, segmented by seven major markets. The report also covers the current EoE treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Eosinophilic Esophagitis Market Outlook

The Eosinophilic Esophagitis market outlook of the report builds a detailed comprehension of the historical, current, and forecasted EoE market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Eosinophilic Esophagitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Eosinophilic Esophagitis market in the 7MM is expected to change in the study period 2018–2030.

Currently, the 3 “D”s (“Drugs, Diet, and Dilation”) are considered the fundamental components of treatment. The first two components, which involve the use of proton pump inhibitors, corticosteroids, immunosuppressants, and empirical diets or guided food elimination based on allergy tests, are more useful in the initial phases, whereas endoscopic dilation is reserved for esophageal strictures. Herein, the most important aspects of eosinophilic Esophagitis pathophysiology will be reviewed, in addition to evidence for the various treatments. There are currently no drugs approved by the Food and Drug Administration for the treatment of EoE.

Key Findings

This section includes a glimpse of the Eosinophilic Esophagitis market in the 7MM. The market size of Eosinophilic Esophagitis in the seven major markets was found to be USD 430.9 million in 2020.

The United States: Market Outlook

This section provides the total Eosinophilic Esophagitis market size and market size by therapies of Eosinophilic Esophagitis in the United States.

The United States accounts for the highest market size of Eosinophilic Esophagitis in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

PPIs are useful as a first-line treatment for patients with EoE. Initial PPI doses of 20-40 mg or 1 mg/kg per dose are given twice daily in adults and children, respectively. The reported response rates to PPI therapy in the EoE population can vary widely from 30–70%. This is likely due to distinct clinical scenarios but there are currently no clinical features that discern a patient who will respond to PPI monotherapy.

Corticosteroids are another effective therapy for the treatment of EoE. The formulation of the most commonly used corticosteroids, including budesonide, fluticasone propionate, and ciclesonide, influences histological remission.

Bougie and balloon dilation is the only endoscopic treatment available for EoE. It is performed in patients with persistent dysphagia resistant to medical treatment in whom remission of inflammation has been achieved and in patients with severe dysphagia and a history of food impaction.

Request for sample pages @ Eosinophilic Esophagitis Market Size 

Table of contents

1. Key Insights

2. Report Introduction

3. Eosinophilic Esophagitis Market Overview at a Glance

3.1. Market Share (%) Distribution of Eosinophilic Esophagitis in 2018

3.2. Market Share (%) Distribution of Eosinophilic Esophagitis in 2030

4. Eosinophilic Esophagitis Patient Split at a Glance

4.1. Patient Split (%) Distribution of Eosinophilic Esophagitis in 2018

4.2. Patient Split (%) Distribution of Eosinophilic Esophagitis in 2030

5. Executive Summary of Eosinophilic Esophagitis

6. Disease Background and Overview

6.1. Introduction

6.2. Clinical Manifestation

6.3. Risk factors associated with EoE

6.4. Phenotypes, Endotypes and Genotype correlation in Eosinophilic Esophagitis

6.5. Pathophysiology

6.6. Diagnosis

6.6.1. Differential Diagnosis

6.6.2. Complexities in EoE Diagnosis

7. Treatment

8. Guidelines for Management of EoE

8.1. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis

8.2. European statements and recommendations on the management of EoE

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. 7MM Total Diagnosed Prevalent Population of Eosinophilic Esophagitis

9.3. Epidemiology of Eosinophilic Esophagitis

9.4. The United States

9.4.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in the United States

9.4.2. Gender-specific cases of Eosinophilic Esophagitis in the United States

9.4.3. Age-specific cases of Eosinophilic Esophagitis in the United States

9.5. EU5

9.5.1. Germany

9.5.1.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in Germany

9.5.1.2. Gender-specific cases of Eosinophilic Esophagitis in Germany

9.5.1.3. Age-specific Cases of Eosinophilic Esophagitis in Germany

9.5.2. France

9.5.2.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in France

9.5.2.2. Gender-specific cases of Eosinophilic Esophagitis in France

9.5.2.3. Age-specific Cases of Eosinophilic Esophagitis in France

9.5.3. Italy

9.5.3.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in Italy

9.5.3.2. Gender-specific cases of Eosinophilic Esophagitis in Italy

9.5.3.3. Age-specific Cases of Eosinophilic Esophagitis in Italy

9.5.4. Spain

9.5.4.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in Spain

9.5.4.2. Gender-specific cases of Eosinophilic Esophagitis in Spain

9.5.4.3. Age-specific Cases of Eosinophilic Esophagitis in Spain

9.5.5. United Kingdom

9.5.5.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in the UK

9.5.5.2. Gender-specific cases of Eosinophilic Esophagitis in the United Kingdom

9.5.5.3. Age-specific Cases of Eosinophilic Esophagitis in the United Kingdom

9.6. Japan

9.6.1.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in Japan

9.6.1.2. Gender-specific cases of Eosinophilic Esophagitis in Japan

9.6.1.3. Age-specific Cases of Eosinophilic Esophagitis in Japan

10. Organizations contributing toward the fight against EoE

11. Patient Journey

12. Case Report

13. Marketed Drug

13.1. Jorveza: Dr Falk Pharma GmbH

13.2. Drug Description

13.3. Regulatory Milestone

13.4. Safety and Efficacy

13.5. Side Effect

13.6. Product Profile

14. Emerging Therapies

14.1. Key Cross Competition

14.2. Budesonide Oral Suspension: Takeda

14.2.1. Drug Description

14.2.2. Other Development Activities

14.2.3. Clinical Development

14.2.4. Clinical Trial Information

14.2.5. Safety and Efficacy

14.2.6. Product Profile

14.3. Dupilumab: Regeneron Pharmaceuticals/Sanofi

14.3.1. Drug Description

14.3.2. Other Development Activities

14.3.3. Clinical Development

14.3.4. Clinical Trial Information

14.3.5. Safety and Efficacy

14.3.6. Product Profile

14.4. Cendakimab: Bristol-Myers Squibb

14.4.1. Drug Description

14.4.2. Other Development Activities

14.4.3. Clinical Development

14.4.4. Clinical Trial Information

14.4.5. Safety and Efficacy

14.4.6. Product Profile

14.5. APT-1011: Ellodi Pharmaceuticals

14.5.1. Drug Description

14.5.2. Other Development Activities

14.5.3. Clinical Development

14.5.4. Clinical trial information

14.5.5. Safety and Efficacy

14.5.6. Product Profile

14.6. Benralizumab: AstraZeneca

14.6.1. Drug Description

14.6.2. Other Development Activities

14.6.3. Clinical Development

14.6.4. Clinical trial information

14.6.5. Product Profile

14.7. Lirentelimab: Allakos

14.7.1. Drug Description

14.7.2. Other Development Activities

14.7.3. Clinical Development

14.7.4. Clinical Trial Information

14.7.5. Safety and Efficacy

14.7.6. Product Profile

15. Other Promising Therapies

15.1. ESO-101: EsoCap AG

15.1.1. Drug Description

15.1.2. Other Development Activities

15.1.3. Clinical Development

15.1.4. Clinical trial information

15.1.5. Product Profile

15.2. Etrasimod: Arena Pharmaceutical

15.2.1. Drug Description

15.2.2. Other Development Activities

15.2.3. Clinical Development

15.2.4. Clinical Trial Information

15.2.5. Product Profile

15.3. Mepolizumab: GlaxoSmithKline

15.3.1. Drug Description

15.3.2. Clinical Development

15.3.3. Clinical Trial Information

15.3.4. Product Profile

16. Eosinophilic Esophagitis: 7 Major Market Analysis

16.1. Key Findings

16.2. Market Size of Eosinophilic Esophagitis in 7MM

16.3. Market Outlook

16.4. United States Market Size

16.4.1. Total Market Size of Eosinophilic Esophagitis in the United States

16.4.2. Market Size of Eosinophilic Esophagitis by Therapies in United States

16.4.3. Market Size of Eosinophilic Esophagitis by Class in the United States

16.5. EU-5 Market Size

16.5.1. Germany

16.5.1.1. Total Market size of Eosinophilic Esophagitis in Germany

16.5.1.2. Market Size of Eosinophilic Esophagitis by Therapies in Germany

16.5.1.3. Market Size of Eosinophilic Esophagitis by Class in Germany

16.5.2. France

16.5.2.1. Total Market size of Eosinophilic Esophagitis in France

16.5.2.2. Market Size of Eosinophilic Esophagitis by Therapies in France

16.5.2.3. Market Size of Eosinophilic Esophagitis by Class in France

16.5.3. Italy

16.5.3.1. Total Market size of Eosinophilic Esophagitis in Italy

16.5.3.2. Market Size of Eosinophilic Esophagitis by Therapies in Italy

16.5.3.3. Market Size of Eosinophilic Esophagitis by Class Italy

16.5.4. Spain

16.5.4.1. Total Market size of Eosinophilic Esophagitis in Spain

16.5.4.2. Market Size of Eosinophilic Esophagitis by Therapies in Spain

16.5.4.3. Market Size of Eosinophilic Esophagitis by Class in Spain

16.5.5. United Kingdom

16.5.5.1. Total Market size of Eosinophilic Esophagitis in United Kingdom

16.5.5.2. Market Size of Eosinophilic Esophagitis by Therapies in United Kingdom

16.5.5.3. Market Size of Eosinophilic Esophagitis by Class in the United Kingdom

16.6. Japan

16.6.1. Total Market size of Eosinophilic Esophagitis in Japan

16.6.2. Market Size of Eosinophilic Esophagitis by Therapies in Japan

16.6.3. Market Size of Eosinophilic Esophagitis by Class in Japan

17. KOL Views

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Unmet Needs

22. Appendix

22.1. Bibliography

22.2. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/atlantanewsonlin/public_html/news.bostonnewsdesk.com/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7
  Categories: